



GCP Clinical Studies response to COVID-19: together with you

Dear Valued Clients, Partners and Industry Colleagues,

We hope that you, your employees and families are all well.

GCP is responding to the challenges we are facing in respect of the coronavirus (COVID-19) and the effect on clinical studies we are managing.

Our priority is the protection of our employees, staff at the hospital sites and patients while ensuring regulatory compliance and data integrity of the studies in our care.

We are carefully monitoring all procedures and instructions issued by the MOH, FDA and local institutions, as well as those of our Sponsors.

At present 90% of our staff is working from home with protected full access to all the systems and support required for study management.

GCP management is in constant contact, internally and externally, and reviewing the situation on a daily basis.

Regular remote meetings are being held with our staff to ensure support.

Our Project Managers are available at all times to support our CRAs and study staff at the Medical Centers.

All institutions have been contacted to assess the local situation.

Monitoring visits and site management:

At present onsite monitoring is not possible due to severe restrictions. Our CRAs will continue monitoring the sites through EDC systems and regular contact with site staff.

We are in contact with the drug /IP suppliers to see that adequate supplies will be on site. We are taking similar actions where appropriate with regards to couriers, laboratories and other study specific requirements.

Regulatory and safety reporting:

At present the Israeli MOH and IECs are continuing to work and hold remote, virtual meetings. At GCP we continue to submit initial submissions to be prepared for when we return to a normal routine, as well as protocol amendments received.

All safety information is appropriately distributed.

Data Management and statistical services:

These services are continuing as well. Our staff is available via e-mails, phone and virtual meetings, as needed.

We are reviewing the situation on a daily basis and will keep you fully updated.

Our study staff are available for any issues or questions you may have. Ahuva and myself can be contacted at any time.

Thank you for your continued support.

We remain committed to supporting you to ensure that the vital delivery of our work continues.

We are confident that working together we will overcome this challenge and return to normal, for happier times in the near future.

Warm regards,

Ahuva Koren
President & CEO
ahuva@gcp.co.il
+972-54-5872788

Stephen Levenstein
VP, Research Division
stephen@gcp.co.il
+972-54-477-2853

About GCP Clinical Studies

Our company is the trusted CRO partner of choice in Israel's exciting pharmaceutical and medical device markets. Proven experience and a therapeutic focus help local and global clients on their journey to success – with predictable outcomes, on time execution and on budget.

Together with the GCP Academy, Israel's most respected Clinical Research Training Center, GCP is shaping the future of clinical research in Israel.

To learn more about us, visit: <https://gcp.co.il/>



GCP Clinical Studies Ltd. | 22 Hamelacha Street, Rosh Haayin, 4809162, Israel | +972-3-9002022

הסר | דווח כספאם

נשלח באמצעות תוכנת ActiveTrail